Search Results
71 Results Found for “transcatheter”
The European Society of Cardiology (ESC) has published its first dedicated clinical practice guidelines on cardiac rehabilitation, calling for rehabilitation to be considered a core component of care across a broader range of cardiovascular conditions. Published in the European Heart ...
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR
Day 2 hotline data at EuroPCR 2026 highlighted improved outcomes with FFR-guided PCI in TAVI, comparable 10-year survival with PCI and CABG in left main disease and consistent LAAC benefits across age groups.
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At EHRA 2026, new research from Dr Kerollos Abdelsayed highlighted perioperative inflammation as a modifiable driver of conduction disturbances after TAVI, opening the door to novel pharmacologic and device-based solutions.
Balloon aortic valvuloplasty (BAV) has experienced a complex evolution in clinical practice, transitioning from an early therapeutic innovation to limited use, and more recently to a redefined role in the era of transcatheter aortic valve implantation (TAVI). In the first of our new practice pearls series, In Rhythm, Dr Gustavo Samaja (Sanatorio Colegiales, Buenos Aires, Argentina) shares practical insights into the contemporary role of BAV, including patient selection, procedural strategies, and its use as both a bridge and a decision-making tool. He also discusses how evolving healthcare systems and resource considerations continue to shape the balance between BAV and TAVI in everyday clinical practice.
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier: NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...
The ESC Congress 2025 congress was an important meeting for clinical practice guidance in cardiology, with several major societies releasing long-awaited updates. As always, clinical practice guidelines remain central to cardiology, ensuring that the latest trial data and real-world evidence are rapidly translated into consistent, evidence-based patient care. This year’s congress saw the unveiling of important new documents across prevention, acute care and long-term management, equipping cardiologists with refined decision pathways, updated risk-stratification tools and clearer benchmarks to optimise patient outcomes.
May 2025 saw several significant developments in the field of cardiology, including new regulatory approvals, long-term clinical trial data and important findings from late-breaking studies. This roundup highlights the latest updates across structural, interventional and heart failure therapies, with implications for ...
Welcome to this issue of Heart International. As ever, we aim to provide our readers with the latest developments, insights, and evidence-based discussions in cardiovascular care. This edition is particularly poignant, as we begin with a heartfelt tribute to an ...
As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the cardiology community with high-quality, easily accessible content.
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
The first-in-human implantation of a leadless pacing system occurred already more than 10 years ago.1 The first-generation ventricular leadless pacemaker could provide only asynchronous ventricular pacing (ventricular, ventricular, inhibited [VVI], or ventricular, ventricular, inhibited, rate response [VVIR]), limiting its indications to ...
The EuroPCR 2024 meeting, the leading global conference in interventional cardiovascular medicine, was a hub of innovation and cutting-edge research. This year’s event in Paris brought together the world's foremost experts, researchers and clinicians to share the latest advancements and breakthroughs in the field. From novel therapeutic approaches to landmark clinical trials, EuroPCR 2024 provided a comprehensive overview of the current and future landscape of cardiovascular care. We selected our top three trials from this year’s late-breaking sessions:
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
